Drug Trial Radar · NCT03485677
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Apr 11, 2018
Primary completion
Dec 26, 2025
Study completion Dec 26, 2025
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: Evaluated the safety and pharmacokinetics of eliglustat in pediatric participants (≥2 to \<18 years old). Secondary Objective: Evaluated the efficacy of eliglustat and quality of life in pediatric participants (≥2 to \<18 years old).
Conditions
- Gaucher's Disease Type I
- Gaucher's Disease Type III
Interventions
Eliglustat GZ385660Drug
Pharmaceutical form: Capsule, Liquid Route of administration: Oral
Imiglucerase GZ437843Drug
Pharmaceutical form: Powder for solution for infusion Route of administration: Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of pharmacokinetic (PK) parameter of eliglustat: CmaxTime frame: Weeks 2, 13, 26 and 52
- Assessment of PK parameter of eliglustat: AUCTime frame: Weeks 2 and 52
- Adverse EventsTime frame: Up to Week 364
Locations
21 sites in 10 countries. Site status is shown where the registry gives one.
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 1240002
Calgary, Alberta, Canada
Investigational Site Number : 1240003
Vancouver, British Columbia, Canada
Investigational Site Number : 1240001
Toronto, Ontario, Canada
Investigational Site Number : 2500002
Bron, France
Investigational Site Number : 3800002
Rome, Roma, Italy
Investigational Site Number : 3920001
Tokyo, Japan
Investigational Site Number : 3920002
Koshigaya, Saitama, Japan
Investigational Site Number : 6430001
Moscow, Russia
Investigational Site Number : 6430004
Moscow, Russia
Investigational Site Number : 6430005
Saint Petersburg, Russia
Investigational Site Number : 6430002
Tomsk, Russia
Investigational Site Number : 7240003
Zaragoza, Spain
Investigational Site Number : 7240001
Esplugues de Llobregat, Barcelona [Barcelona], Spain
Investigational Site Number : 7240002
Barakaldo, Basque Country, Spain
Investigational Site Number : 7520002
Gothenburg, Sweden
Investigational Site Number : 7520001
Luleå, Sweden
Investigational Site Number : 7920004
Adana, Turkey (Türkiye)
Investigational Site Number : 7920003
Istanbul, Turkey (Türkiye)
Investigational Site Number : 7920002
Izmir, Turkey (Türkiye)
Investigational Site Number : 8260002
Birmingham, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.